Abstracts tagged "Disease Activity"

Abstract Number: 468 • 2013 ACR/ARHP Annual Meeting
The Differential Role Of T Helper Cells In The Pathogenesis and Responsiveness To Abatacept Therapy In Rheumatoid Arthritis
Shunsuke Fukuyo¹, Shingo Nakayamada², Kunihiro Yamaoka¹, Satoshi Kubo¹, Shigeru Iwata³, Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, Kitakyushu, Japan
Background/Purpose: Abatacept (ABT) works through a different mechanism of action from TNF inhibitors in the treatment of rheumatoid arthritis (RA). ABT decreases T cell responses…
Abstract Number: 2681 • 2013 ACR/ARHP Annual Meeting
Reduced Fertility In Women With Rheumatoid Arthritis: Influence Of Disease Activity and Medication Use
Jenny Brouwer^1,2, Johanna MW Hazes¹, Joop SE Laven² and Radboud JEM Dolhain¹, ¹Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ²Obstetrics & Gynaecology, division of Reproductive Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands
Background/Purpose: Many female rheumatoid arthritis (RA) patients who try to conceive have a time to pregnancy (TTP) longer than 12 months. During this period RA…
Abstract Number: 2273 • 2013 ACR/ARHP Annual Meeting
Patient Survey Challenges Conventional Notions Regarding Symptoms and Experiences Of People Living With Rheumatoid Arthritis
Kelly O'Neill Young¹, Cynthia S. Crowson² and Dana M. Symons¹, ¹Rheumatoid Patient Foundation, Cocoa, FL, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: While rheumatoid arthritis (RA) has been studied for decades, many aspects of the disease are not well understood. Like systemic lupus erythematosus, RA manifests…
Abstract Number: 1877 • 2013 ACR/ARHP Annual Meeting
A Neutrophil Signature Comprised Of Low Density Granulocyte (LDG)-Enriched Genes Is Associated With Organ-Specific Disease Activity In Systemic Lupus Erythematosus
Michelle Petri¹, Hong Fang¹, Jadwiga Bienkowska², Andrea Dearth³, Norm Allaire⁴ and Ann Ranger³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Translational Medicine, Biogen Idec Inc., Cambridge, MA, ³Biogen Idec Inc, Cambridge, MA, ⁴Biogen Idec Inc., Cambridge, MA
Background/Purpose: The neutrophil gene signature (NGS) has recently gained interest due to new understanding of the role of neutrophils and NETosis in SLE pathogenesis. We…
Abstract Number: 1425 • 2013 ACR/ARHP Annual Meeting
Discontinuation Of Tumor Necrosis Factor Inhibitors In Rheumatoid Arthritis Patients In Low Disease Activity: Persistent Benefits
Arthur Kavanaugh¹, Susan J. Lee^2,3, Daniel H. Solomon⁴, Jeffrey D. Greenberg⁵, Joel M. Kremer⁶, Lilian Soto⁷, Carol J. Etzel^8,9 and George W. Reed¹⁰, ¹University of California, San Diego, La Jolla, CA, ²University of California San Diego, La Jolla, CA, ³San Diego Veterans Affairs Medical Center, San Diego, CA, ⁴Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁵NYU Hospital for Joint Diseases, New York, NY, ⁶Center for Rheumatology, Albany Medical College, Albany, NY, ⁷University of California San Diego, San Diego, CA, ⁸Department of Epidemiology, UT MD Anderson, Houston, TX, ⁹PO Box 786, Corrona, LLC., Southborough, MA, ¹⁰Corrona, LLC., Southborough, MA
Background/Purpose: A key question is whether biologic agents can be stopped but clinical benefit maintained for rheumatoid arthritis (RA) patients (pts) in remission or low…
Abstract Number: 1103 • 2013 ACR/ARHP Annual Meeting
Brain Derived Neurotrophic Factor Is Elevated In Patients With Rheumatoid Arthritis and Secondary Fibromyalgia
Able Lawrence, Venkatesh Pai, Rajni Srivastava, Vikas Agarwal, Ramnath Misra and Amita Aggarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Secondary Fibromyalgia is seen in 15% of patients with rheumatoid arthritis (RA). Neurotrophins are elevated in patients with active arthritis and BDNF is elevated…
Abstract Number: 451 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Disease Activity By The Routine Assessment Of Patient Index Data 3 In Patients With Rheumatoid Arthritis Receiving Tocilizumab
Yu F. Asanuma¹, Takashi Maruyama², Maiko Yanagisawa², Kazuhiro Yokota³, Yoshihiro Yoshida², Hiroshi Kajiyama¹, Kojiro Sato¹, Yuji Akiyama¹ and Toshihide Mimura⁴, ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ²Saitama Medical University, Saitama, Japan, ³Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ⁴Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Interleukin-6 (IL-6) has been demonstrated to play a pathological role in rheumatoid arthritis (RA). IL-6 strongly induces production of C-reactive protein (CRP) and fibrinogen…
Abstract Number: 2683 • 2013 ACR/ARHP Annual Meeting
Application Of a Multi-Biomarker Disease Activity (Vectra^® DA) Score For Assessing Rheumatoid Arthritis Patients With Fibromyalgia Or Low C-Reactive Protein
Yvonne C. Lee¹, James Hackett², Claire Alexander³, Michelle A. Frits¹, Christine K. Iannaccone¹, Nancy A. Shadick⁴, Michael E. Weinblatt⁵, Oscar Segurado⁶ and Eric H. Sasso⁶, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Hackett & Associates, Inc., San Diego, CA, ³Clinical Operations, Crescendo Bioscience Inc., South San Francisco, CA, ⁴Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, ⁶Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: Clinical assessment of rheumatoid arthritis (RA) may be challenging if patients have fibromyalgia (FM) or if C-reactive protein (CRP) is low (£1 mg/dL). A…
Abstract Number: 2279 • 2013 ACR/ARHP Annual Meeting
Assessment Of Global Disease Activity In Rheumatoid Arthritis By Patients and Physicians: Cultural Differences Among Countries In The Meteor Database
E. Gvozdenovic¹, R. Wolterbeek², C.F. Allaart¹, Claiton Brenol³, Arvind Chopra⁴, Maxime Dougados⁵, Paul Emery⁶, D. van der Heijde⁷, T.W.J. Huizinga¹, Jonathan Kay⁸, Emilio Martín Mola⁹, Robert J. Moots¹⁰, José A. P. Da Silva¹¹, Josef S. Smolen¹², Douglas J. Veale¹³ and R. Landewe¹⁴, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Biostatistics, Leiden University Medical Center, Leiden, Netherlands, ³Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil, ⁴Rheumatology, Center for Rheumatic Diseases, Pune, India, ⁵Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁶Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁹Rheumatology. La Paz Hospital. IdiPaz, Madrid, Spain, ¹⁰Clinical Sciences Centre, University of Liverpool, Liverpool, United Kingdom, ¹¹Serviço de Reumatologia, Centro Hospitalar e Universitário de Coimbra – Hospitais da Universidade de Coimbra, E.P.E., Coimbra, Portugal, ¹²Medical University of Vienna, Vienna, Austria, ¹³Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ¹⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Dissonant perceptions of disease activity between rheumatoid arthritis (RA) patients and their rheumatologists may influence treatment decisions. The discordance between patient's and physician's global…
Abstract Number: 1863 • 2013 ACR/ARHP Annual Meeting
SLE Disease Activity In The Mucocutaneus, Vascular and Hematologic Systems Is Associated With An Increase In Plasma Type I Interferon Activity
Elena Gkrouzman¹, Mikhail Olferiev¹, Margaret Robotham¹, Mari Lliguicota¹, Wei-Ti Huang², Elzbieta E. Jacek¹, Kyriakos A. Kirou¹ and Mary K. Crow³, ¹Hospital for Special Surgery, New York, NY, ²Biostatistics, Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Type I interferon (IFN-I) has been implicated in SLE pathogenesis, and cross-sectional studies have shown that IFN-I pathway activation is associated with multiple disease…
Abstract Number: 1433 • 2013 ACR/ARHP Annual Meeting
Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS28-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis
Edward Keystone¹, MC Genovese², Peter Taylor³, Baojin Zhu⁴, Scott D. Beattie⁴, Stephanie de Bono⁴, Terence Rooney⁴, Douglas E. Schlichting⁴ and William Macias⁴, ¹University of Toronto, Toronto, ON, Canada, ²Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ³NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib, an oral inhibitor of JAK1 and JAK2 activity, was investigated as treatment for patients with moderately to severely active RA despite use…
Abstract Number: 1026 • 2013 ACR/ARHP Annual Meeting
Impact Of Basing Rheumatoid Arthritis Disease Activity Measurement and Treatment Recommendations On Patient Instead Of Physician Joint Assessments
Yomei Shaw¹, Daisy Bang², Heather Eng³, Stephen R. Wisniewski⁴, Mark S. Roberts¹ and Marc C. Levesque⁵, ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, ³Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁴Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Current guidelines recommend treatment for rheumatoid arthritis (RA) be informed by a measure of disease activity such as the Disease Activity Score-28 (DAS28-CRP), which…
Abstract Number: 422 • 2013 ACR/ARHP Annual Meeting
Disease Activity In Rheumatoid Arthritis Is Associated With Abnormal Left Ventricular Geometry
Helga Midtbø¹, Eva Gerdts^1,2, Inge C. Olsen³, Tore K. Kvien⁴, Einar Davidsen¹ and Anne Grete Semb³, ¹Department of Heart Disease, Haukeland University Hospital, Bergen, Norway, ²Department of Cinical Science, University of Bergen, Bergen, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose :Disease activity is related to risk of cardiovascular (CV) disease in rheumatoid arthritis (RA) patients1,2. Left ventricular (LV) geometry strongly predicts CV mortality and…
Abstract Number: 2663 • 2013 ACR/ARHP Annual Meeting
Moving Towards Personalized Healthcare: A Patient Reported Outcome Based Algorithm Can Aid Rheumatologists and Patients In Monitoring Rheumatoid Arthritis In Daily Clinical Practice
Jos Hendrikx¹, Jaap Fransen², Alessandro Toniolo³ and Piet L.C.M. van Riel⁴, ¹Rheumatology (470), Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Pfizer Pharmaceuticals, Rome, Italy, ⁴Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Several Patient Reported Outcome (PRO)-based instruments to measure disease activity in Rheumatoid Arthritis (RA) exist, though an evidence base for their use in monitoring…
Abstract Number: 2280 • 2013 ACR/ARHP Annual Meeting
Stiffness From The Perspective Of People Living With Rheumatoid Arthritis
Ana-Maria Orbai¹, Katherine Clegg-Smith², Susan J. Bartlett³, Elaine De Leon⁴, Michelle Jones⁵ and Clifton O. Bingham III¹, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Health Behavior and Society, Johns Hopkins University School of Public Health, Baltimore, MD, ³Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁴Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁵Johns Hopkins University, Baltimore, MD
Background/Purpose: Stiffness was included in the 1961 and 1987 Rheumatoid Arthritis (RA) classification criteria and continues to be commonly queried in clinical care. Its relative…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].